Expert-driven custom antibody discovery provides the specificity, stability, and developability needed for the clinic.
Technology diversity delivers solutions tailored to complex targets and therapeutic applications across all disease areas.
Over 140 successful industry partnerships since 2009, with many programs progressing from discovery into the clinic.
Access high-quality synthetic and immune libraries delivering therapeutic antibodies for the clinic.
Transform leads into high-affinity, developable candidates through guided engineering and real-time screening.
Engineer multispecifics, including T-cell engagers, of diverse formats for function, manufacturability, and scalability.
Leverage AI-guided engineering of non-antibody proteins for tailored binding, stability, and expression.
Spanning early discovery to lead optimization, Adimab’s yeast-based platform sets up a strong foundation for successful therapeutic antibody development. Our fully human IgG and HCAb libraries are computationally designed for diversity, specificity, and developability, reducing downstream risk in development.
By addressing liabilities such as hydrophobicity and polyspecific reactivity at the design stage, we generate high-quality candidates primed for clinical translation.
Beyond lead identification, we extend the potential of therapeutic antibodies through targeted maturation, liability mitigation, and precision engineering. Our modular framework supports multispecifics, T cell engagers, soluble TCRs, and emerging formats.
From library designs to focused selections and comprehensive characterization, we iterate and refine leads to deliver ideal candidates for your indication of interest.
Defining biophysical boundaries that guide antibody developability and improve clinical success rates.
Llama-derived CD3 HCAbs streamline T-cell engager design, combining stability, potency, and modularity.
Yeast-based engineering yields high-affinity soluble TCRs, enabling potent, precise T cell therapeutics.